LLP Investigates Centessa's Transaction with Lilly for Fiduciary Breaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy CNTA?
Source: PRnewswire
- Transaction Details: In the deal between Centessa and Lilly, shareholders will receive $38 per share in cash plus contingent value rights worth up to $9, indicating a high return potential in the merger but raising concerns about board conduct.
- Regulatory Investigation: LLP is investigating whether Centessa's board has breached fiduciary duties to all shareholders, particularly regarding restrictions on competing transactions and potential penalties, which could impact corporate governance.
- Contingent Value Rights: The transaction includes contingent value rights with milestone payments of $2, $5, and $2 upon FDA approvals, reflecting Centessa's potential gains in drug development but adding complexity to the deal.
- Insider Benefits: Centessa insiders will receive substantial benefits under change of control arrangements, raising concerns about whether they prioritize personal interests over those of all shareholders, potentially affecting investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to fall
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.760
Low
27.00
Averages
38.75
High
62.00
Current: 39.760
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Apellis Pharmaceuticals, KORE Group Holdings, and Centessa Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Apellis Transaction Details: Apellis Pharmaceuticals is being sold to Biogen Inc. for $41.00 per share in cash, along with a non-transferable right to receive two payments of $2.00 each, contingent on meeting specific global net sales thresholds, potentially affecting shareholder returns.
- KORE Transaction Situation: KORE Group Holdings is being sold for $9.25 per share to Searchlight Capital Partners and Abry Partners, prompting shareholders to consider the implications of this transaction on their rights and available legal options.
- Centessa Transaction Analysis: Centessa Pharmaceuticals is being sold for $38.00 per share in cash, plus a non-transferable right entitling holders to receive up to $9.00 upon achieving certain milestones, urging shareholders to understand their legal rights and options.
See More
Monteverde Law Firm Investigates Multiple Biotech Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals Inc., with Kezar shareholders expected to receive $6.955 per share in cash and a non-transferable contingent value right, aiming to protect shareholder interests and ensure transaction fairness.
- Centessa Transaction Details: In the deal between Centessa Pharmaceuticals plc and Eli Lilly, Centessa shareholders are anticipated to receive $38.00 per share in cash along with a contingent value right that could yield up to $9.00 based on certain milestones, demonstrating the company's commitment to shareholder value.
- Talkspace Shareholder Rights: In the transaction involving Talkspace, Inc. and Universal Health Services, Inc., Talkspace shareholders will receive $5.25 per share in cash, indicating the deal aims to provide direct cash returns to shareholders and enhance their confidence.
- Warner Bros. Transaction Progress: Warner Bros. Discovery, Inc. is set to receive $31.00 per share in cash and additional compensation based on elapsed time in its deal with Paramount Skydance Corporation, with a shareholder vote scheduled for April 23, 2026, reflecting the company's transparency and the importance of shareholder engagement in mergers.
See More
Investigation into Centessa's Transaction with Lilly for Possible Violations
- Shareholder Compensation Structure: Centessa shareholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share in the transaction with Lilly, indicating a commitment to short-term shareholder returns while raising concerns about long-term value.
- Milestone Payment Conditions: The contingent value rights include three milestone payments of $2.00 for FDA approval of narcolepsy treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030, which may influence the company's future R&D direction.
- Board Responsibility Investigation: Ademi LLP is investigating whether Centessa's board fulfilled its fiduciary duties to all shareholders in light of the significant penalties imposed on competing transactions, which could have legal implications.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Centessa for accepting competing bids, potentially limiting future market opportunities and negatively impacting shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) regarding its sale to Biogen Inc. for $41.00 per share in cash and two contingent value rights of $2.00 each, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The firm encourages Apellis shareholders to understand their legal rights and options, emphasizing free consultations to ensure that shareholder interests are protected in the transaction.
- Additional Company Investigations: Centessa Pharmaceuticals plc (NASDAQ:CNTA) is also under scrutiny for its sale to Eli Lilly for $38.00 per share plus a contingent value right of up to $9.00, with Halper Sadeh LLC investigating possible breaches of fiduciary duties.
- Legal Relief Measures: Halper Sadeh LLC represents investors globally, seeking increased consideration, additional disclosures, or other relief to advocate for the rights of affected shareholders.
See More
Sysco and McCormick Announce Major Acquisitions
- Sysco Acquisition Update: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across 700,000 restaurants, although it faces potential antitrust scrutiny that could complicate the deal.
- McCormick and Unilever Merger: McCormick announced a $44 billion merger with Unilever's food division, despite being valued at only $14 billion itself, indicating a strategic move to leverage scale and synergies, though past similar deals have often failed to deliver expected value.
- M&A Activity in Food Sector: The recent surge in mergers within the food industry highlights a market trend towards consolidation and economies of scale, yet historical data suggests that many large consumer brand mergers have not yielded positive outcomes, prompting investors to proceed with caution.
- Eli Lilly's Centessa Acquisition: Eli Lilly is acquiring Centessa Pharmaceuticals for $7.8 billion, focusing on expediting the market entry of a promising narcolepsy treatment, despite Centessa lacking commercial products, with success hinging on upcoming clinical trial results.
See More
Surge in M&A Activity in the Food Sector
- Sysco Acquisition Move: Sysco is acquiring Restaurant Depot for $26 billion, aiming to enhance its supply chain efficiency across its network of 700,000 restaurants, thereby solidifying its leadership position in the U.S. food service distribution market.
- McCormick and Unilever Merger: McCormick announced a merger with Unilever's food division valued at $44 billion, despite McCormick's market cap of only $14 billion, indicating a strategy to leverage scale and resource integration for improved profitability, though it faces integration risks.
- Market Reactions and Risks: Analysts express caution regarding both Sysco and McCormick's transactions, particularly with Sysco taking on $21 billion in new debt, which could impact its financial stability, while the success of McCormick's merger strategy remains to be seen.
- Eli Lilly Acquires Centessa: Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on rare disease treatments; if FDA approval is secured, it could tap into a $5 billion market, reflecting strong demand and investment willingness in the pharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating companies like Apellis Pharmaceuticals, KORE Group Holdings, and Centessa Pharmaceuticals for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Apellis Transaction Details: Apellis Pharmaceuticals is being sold to Biogen Inc. for $41.00 per share in cash, along with a non-transferable right to receive two payments of $2.00 each, contingent on meeting specific global net sales thresholds, potentially affecting shareholder returns.
- KORE Transaction Situation: KORE Group Holdings is being sold for $9.25 per share to Searchlight Capital Partners and Abry Partners, prompting shareholders to consider the implications of this transaction on their rights and available legal options.
- Centessa Transaction Analysis: Centessa Pharmaceuticals is being sold for $38.00 per share in cash, plus a non-transferable right entitling holders to receive up to $9.00 upon achieving certain milestones, urging shareholders to understand their legal rights and options.
See More
Monteverde Law Firm Investigates Multiple Biotech Companies
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals Inc., with Kezar shareholders expected to receive $6.955 per share in cash and a non-transferable contingent value right, aiming to protect shareholder interests and ensure transaction fairness.
- Centessa Transaction Details: In the deal between Centessa Pharmaceuticals plc and Eli Lilly, Centessa shareholders are anticipated to receive $38.00 per share in cash along with a contingent value right that could yield up to $9.00 based on certain milestones, demonstrating the company's commitment to shareholder value.
- Talkspace Shareholder Rights: In the transaction involving Talkspace, Inc. and Universal Health Services, Inc., Talkspace shareholders will receive $5.25 per share in cash, indicating the deal aims to provide direct cash returns to shareholders and enhance their confidence.
- Warner Bros. Transaction Progress: Warner Bros. Discovery, Inc. is set to receive $31.00 per share in cash and additional compensation based on elapsed time in its deal with Paramount Skydance Corporation, with a shareholder vote scheduled for April 23, 2026, reflecting the company's transparency and the importance of shareholder engagement in mergers.
See More
Investigation into Centessa's Transaction with Lilly for Possible Violations
- Shareholder Compensation Structure: Centessa shareholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share in the transaction with Lilly, indicating a commitment to short-term shareholder returns while raising concerns about long-term value.
- Milestone Payment Conditions: The contingent value rights include three milestone payments of $2.00 for FDA approval of narcolepsy treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030, which may influence the company's future R&D direction.
- Board Responsibility Investigation: Ademi LLP is investigating whether Centessa's board fulfilled its fiduciary duties to all shareholders in light of the significant penalties imposed on competing transactions, which could have legal implications.
- Restrictions on Competing Transactions: The transaction agreement imposes significant penalties on Centessa for accepting competing bids, potentially limiting future market opportunities and negatively impacting shareholder interests.
See More
